Short-course Methenamine Hippurate for Prevention of Post-operative UTI
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The investigators will determine the efficacy of an innovative short regimen of methenamine
hippurate on prevention of post-operative UTI in patients requiring short-term
catheterization after pelvic reconstructive surgery through a single-blind, randomized
controlled trial. Primary outcome will be the rate of symptomatic UTI within 3 weeks of
catheter removal. The investigators will study cost-effectiveness, antibiotic resistance
profiles, and adverse drug effects. Findings may reduce antibiotic use and nosocomial UTIs.